FrancophonIA/ELRC3.0 huggingface dataset:
English: Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t1/2) of 16.8 hours.
Estonian: Tippkontsentratsioonile järgnes süsteemse mõju langus poolväärtusajaga (t1/2) 16,8 tundi.
English: The use of Cerenia solution for injection against vomiting due to motion sickness is not recommended.
Estonian: Cerenia süstelahust ei soovitata kasutada kinetoosist ehk merehaigusest põhjustatud oksendamise vastu.
English: To prevent vomiting, Cerenia solution for injection should be administered more than 1 hour in advance.
Estonian: Oksendamise vältimiseks tuleb Cerenia süstelahust manustada 1 tund enne võimalikku oksendamist.
English: • For the treatment and prevention of nausea induced by chemotherapy.
Estonian: • Kemoteraapiast tingitud iivelduse raviks ja ärahoidmiseks.
English: The solution for injection contains 10 mg maropitant per ml as maropitant citrate monohydrate as a clear, colourless to light yellow solution.
Estonian: Süstelahus sisaldab 10 mg/ml maropitanti maropitanttsitraadina selges värvitus kuni kergelt kollases lahuses.
English: • For the prevention of nausea induced by chemotherapy.
Estonian: • Kemoteraapiast tingitud iivelduse ärahoidmiseks.
English: • For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness.
Estonian: • Oksendamise ärahoidmiseks ja iivelduse vähendamiseks, väljaarvatud kinetoosist e merehaigusest tingitud juhtudel.
English: It is therefore recommended to initiate the treatment of emesis with Cerenia solution for injection.
Estonian: Seetõttu on soovitav kasutada esmalt süstitavat preparaati Cerenia solution for injection.
English: Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t1/2) of 8.84 hours.
Estonian: Tippkontsentratsioonile järgnes süsteemse mõju langus poolväärtusajaga (t1/2) 8,84 tundi.
English: The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to cats was characterised by a maximum concentration (Cmax) in plasma of approximately 165 ng/ml; this was achieved on average 0.32 hours (19 min) post-dosing (Tmax).
Estonian: Maropitandi farmakokineetilist profiili kassidele ühekordsel subkutaansel manustamisel annuses 1 mg/kg kehamassi kohta iseloomustasid maksimaalne kontsentratsioon (Cmax) plasmas umbes 165 ng/ml; see saavutati keskmiselt 0,32 tunni (19 minuti) jooksul pärast manustamist (Tmax).
English: Maropitant is a potent and selective neurokinin (NK-1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family, in the CNS.
Estonian: Maropitant on tugev ja selektiivne neurokiniini (NK-1) retseptori antagonist, mis toimib inhibeerides P-aine, tahhükiniini perekonna neuropeptiidi, sidumist KNS-is.
English: Tablets are breakable along the score line on the tablet.
Estonian: Tablette saab murda piki poolitusjoont.
English: In dogs, Cerenia can be used to treat or prevent vomiting either as tablets or as solution for injection administered once daily.
Estonian: Koertel võib Cereniat kasutada oksendamise ravimiseks või ärahoidmiseks kord päevas manustatavate tablettide või süstelahusena.
English: The safety of the veterinary medicinal product has not been established in dogs less than 16 weeks of age for the 8 mg/kg dose (motion sickness), and in dogs less than 8 weeks of age for the 2 mg/kg dose (vomiting) as well as in pregnant or lactating bitches.
Estonian: Selle preparaadi ohutus alla 16-nädalastele koertele annuses 8 mg/kg (merehaigus), alla 8-nädalastele koertele annuses 2 mg/kg (oksendamine) ja ka tiinetele või lakteerivatele koertele ei ole kindlaks tehtud.
English: The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to dogs was characterised by a maximum concentration (Cmax) in plasma of approximately 92 ng/ml; this was achieved within 0.75 hours post-dosing (Tmax).
Estonian: Maropitandi farmakokineetilist profiili koertele ühekordsel subkutaansel manustamisel annusena 1 mg/kg kehamassi kohta iseloomustasid maksimaalne kontsentratsioon (Cmax) plasmas umbes 92 ng/ml; see saavutati 0,75 tunni jooksul pärast manustamist (Tmax).
English: Cerenia should be used with caution in animals suffering from or with predisposition for heart diseases.
Estonian: Südamehaigust põdevatel või südamehaiguste eelsoodumusega loomadel peaks Cereniat kasutama ettevaatlikult.
English: As maropitant is accumulated in the body during a 14-day treatment period due to metabolic saturation, careful monitoring of liver function in addition to any adverse events should be implemented during long term treatment.
Estonian: Kuna maropitant kuhjub 14-päevase raviperioodi jooksul organismis metaboolse küllastumise tõttu, siis on pikaaegse ravi korral vajalik peale mis tahes kõrvaltoimete jälgida hoolikalt ka maksatalitlust.
English: The pharmacokinetic profile of maropitant when administered as a single oral dose of 2 mg/kg body weight to dogs was characterised by a maximum concentration (Cmax) in plasma of approximately 81 ng/ml; this was achieved within 1.9 hours post-dosing (Tmax).
Estonian: Maropitandi farmakokineetilist profiili koertele ühekordsel suukaudsel manustamisel annuses 2 mg/kg kehamassi kohta iseloomustasid maksimaalne kontsentratsioon (Cmax) plasmas umbes 81 ng/ml; see saavutati 1,9 tunni jooksul pärast manustamist (Tmax).
English: Dog body weight (kg)
Estonian: Koera kehamass (kg)
English: Pain at injection site may occur when injected subcutaneously.
Estonian: Subkutaanse manustamisel korral võib esineda valulikkust süstekohal.
English: Increases of approximately 10% in the QT interval of the ECG were observed in a study on healthy beagle dogs administered 8 mg/kg orally; however, such an increase is unlikely to be of clinical significance.
Estonian: Tervetel beagle tõugu koertel läbi viidud uurimus näitas, et loomade EKG QT intervall suurenes 10%, kui neile oli suukaudselt manustatud ravimit annuses 8 mg/kg.
English: The duration of the effect is approximately 24 hours and, therefore, tablets can be given the night before administration of an agent that may cause emesis (e.g. chemotherapy).
Estonian: Toime kestab umbes 24 tundi, seega võib tablette anda oksendamist esile kutsuvale tegurile (näit.
English: Signs of nausea in dogs including excessive salivation and lethargy might remain after treatment.
Estonian: Koertel võivad iivelduse tunnused nagu ilavool ja letargia säilida vaatamata ravile.
English: CYP2D15 and CYP3A12 were identified as the canine isoforms involved in the hepatic biotransformation of maropitant.
Estonian: Maropitandi maksabiotransformatsioonil osalevate kaniinsete isoformidena identifitseeriti CYP2D15 ja CYP3A12.
English: Maropitant is a neurokinin 1 (NK1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family.
Estonian: Maropitant on neurokiniini 1(NK1) retseptori antagonist, mis toimib inhibeerides P-aine, tahhükiniini perekonna neuropeptiidi, sidumist kesknärvisüsteemis.
English: Following repeated oral administration for five consecutive days at a daily dose of 2 mg/kg, accumulation was 151%.
Estonian: Pärast korduvat suukaudset manustamist viiel järjestikusel päeval annuses 2 mg/kg oli maropitandi akumuleeruvus 151%.
English: The elimination t1/2 following intravenous dosing was approximately 4.9 h. There appears to be an age-related effect on the pharmacokinetics of maropitant in cats with kittens having higher clearance than adults.
Estonian: Kassidel näib esinevat ealine efekt maropitandi farmakokineetikale, millest tulenevalt on kassipoegadel suurem kliirens kui täiskasvanud kassidel.
English: Cerenia can be used to treat or prevent vomiting either as tablets or as solution for injection administered once daily.
Estonian: Cereniat võib kasutada oksendamise ravimiseks või ärahoidmiseks kord päevas manustatavate tablettide või süstelahusena.
English: Following repeated subcutaneous administration of once-daily doses of 1 mg/kg bodyweight for five consecutive days, accumulation was 146%.
Estonian: Pärast korduvat subkutaanset manustamist viiel järjestikusel päeval annusena 1 mg/kg oli maropitandi akumuleeruvus 146%.
English: To prevent vomiting induced by motion sickness, Cerenia tablets should be administered once daily, at a dose of 8 mg maropitant per kg bodyweight, using the numbers of tablets given in the table below.
Estonian: Merehaigusest tingitud oksendamise ärahoidmiseks manustatakse Cerenia tablette üks kord päevas annuses 8 mg maropitanti kehamassi kg kohta, kasutades alltoodud tabelis näidatud tablettide arvu.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Glass vial / Solution for injection
Estonian: MINIMAALSED ANDMED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL
English: Renal and faecal clearances are minor routes of elimination for maropitant, with less than 1% of a 1 mg/kg subcutaneous dose appearing in the urine or faeces as maropitant.
Estonian: Neerude kaudu ja roojaga väljutatakse väike osa maropitandist, uriinis või roojas leidub maropitanti alla 1% subkutaansest 1 mg/kg annusest.
English: • Find the pull-back notch (or cut) as shown by the arrow symbol .
Estonian: • Seejärel rebige või lõigake piki  sümboliga märgistatud sälku.
English: Apart from transient reactions at the injection site following subcutaneous administration, Cerenia solution for injection was well tolerated in dogs and young cats injected daily with up to 5 mg/kg (5 times the recommended dose) for 15 consecutive days (3-times the recommended duration of administration).
Estonian: Uuringutel, kus ravimit süstiti kuni 5 mg/kg päevas (5-kordne soovitatav annus) 15 järjestikusel päeval (3-kordne soovitatav manustamise pikkus), talusid koerad ja noored kassid Cerenia süstelahust hästi, kui välja arvata mööduvad reaktsioonid süstekohal pärast subkutaanset manustamist.
English: To treat and/or prevent vomiting except motion sickness, Cerenia tablets should be administered once daily, at a dose of 2 mg maropitant per kg bodyweight, using the number of tablets given in the table below.
Estonian: Merehaigusest mittetingitud oksendamise ravimiseks ja/või ärahoidmiseks peaks Cerenia tablette manustama üks kord päevas annuses 2 mg maropitatanti kg kehamassi kohta, kasutades alltoodud tabelis näidatud tablettide arvu.
English: 3.3 mg
Estonian: 3,3 mg/ml.
English: Renal clearance is a minor route of elimination, with less than 1% of an 8 mg/kg oral dose appearing in the urine as either maropitant or its major metabolite.
Estonian: Neerude kaudu väljutatakse väike osa maropitandist, uriinis leidub kas maropitanti või selle peamist metaboliiti alla 1% suukaudsest 8 mg/kg annusest.
English: Following repeated subcutaneous administration of once-daily doses of 1 mg/kg bodyweight for five consecutive days, accumulation was 250%.
Estonian: Pärast korduvat subkutaanset manustamist viiel järjestikusel päeval annuses 1 mg/kg oli maropitandi akumuleeruvus 250%.
English: It is recommended to initiate treatment of emesis with Cerenia solution for injection.
Estonian: Soovitatav on alustada oksendamise ravi Cerenia süstelahusega.
English: Renal clearance is a minor route of elimination, with less than 1% of a 1 mg/kg subcutaneous dose appearing in the urine as either maropitant or its major metabolite.
Estonian: Neerude kaudu väljutatakse väike osa maropitandist, uriinis leidub kas maropitanti või selle peamist metaboliiti alla 1% subkutaansest 1 mg/kg annusest.
English: To treat or prevent vomiting, Cerenia tablets should be administered once daily, at a dose of 2 mg maropitant per kg bodyweight, using the number of tablets given in the table below.
Estonian: Oksendamise ravimiseks ja/või ärahoidmiseks peaks Cerenia tablette manustama üks kord päevas, annuses 2 mg maropitanti kehamassi kg kohta, kasutades alltoodud tabelis näidatud tablettide arvu.
English: Incidents of pre-travel vomiting, usually within two hours post-dosing were commonly reported after administration of the 8 mg/kg dose.
Estonian: Koertel on maropitandi manustamine annuses 8 mg/kg põhjustanud reisieelset oksendamist, tavaliselt 2 tunni jooksul pärast manustamist.
English: The safety of the veterinary medicinal product has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or lactating dogs and cats.
Estonian: Selle preparaadi ohutus alla 8-nädalastele koertele või alla 16-nädalastele kassidele ning tiinetele ja lakteerivatele koertele ja kassidele ei ole kindlaks tehtud.
English: Clinical signs including vomiting on first administration, excess salivation and watery faeces have been observed when the product has been overdosed in excess of 20 mg/kg.
Estonian: Koertel, kellele manustati 20 mg/kg üleannus, täheldati kliinilisi nähte, sealhulgas oksendamist esimesel manustamisel, liigset süljevoolu ja vedelat väljaheidet.
English: Each tablet contains 24 mg maropitant as maropitant citrate monohydrate.
Estonian: Iga tablett sisaldab 24 mg maropitanti maropitanttsitraatmonohüdraadina.
English: The effect duration is approximately 24 h and therefore treatment can be given the night before administration of an agent that may cause emesis e.g. chemotherapy.
Estonian: Toime kestab umbes 24 tundi, seega võib ravimit manustada oksendamist esile kutsuvale tegurile, näit.
English: • For the prevention of vomiting except that induced by motion sickness.
Estonian: • Oksendamise ärahoidmiseks, väljaarvatud kinetoosist e merehaigusest tingitud juhtudel.
English: Each tablet contains 16 mg maropitant as maropitant citrate monohydrate.
Estonian: Iga tablett sisaldab 16 mg maropitanti maropitanttsitraatmonohüdraadina.
English: By inhibiting the binding of substance P within the emetic centre, maropitant is effective against neural and humoral (central and peripheral) causes of vomiting.
Estonian: Maropitant toimib oksendamise neuraalsete ja humoraalsete (tsentraalsete ja perifeersete) põhjuste vastu inhibeerides P-aine sidumist oksekeskuses.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box / Solution for injection
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Pappkarp/süstelahus
English: Prolonged fasting before administration should be avoided.
Estonian: Vältima peab pikemat söömata olemist enne tableti andmist.
English: Each tablet contains 160 mg maropitant as maropitant citrate monohydrate.
Estonian: Iga tablett sisaldab 160 mg maropitanti maropitanttsitraatmonohüdraadina.
English: − rare (more than 1 but less than 10 animals in 10,000 animals treated)
Estonian: - Väga sage (kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - Sage (rohkem kui 1-l, kuid vähem kui 10-l loomal 100-st ravitud loomast) - Aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st ravitud loomast) - Harv (rohkem kui 1-l, kuid vähem kui 10-l loomal 10000-st ravitud loomast)
English: Each tablet contains 60 mg maropitant as maropitant citrate monohydrate.
Estonian: Iga tablett sisaldab 60 mg maropitanti maropitanttsitraatmonohüdraadina.
English: It also contains metacresol (as preservative).
Estonian: Lahus sisaldab säilitusainena metakresooli.
English: Maropitant displays linear kinetics when administered subcutaneously within the 0.25-3 mg/kg dose range.
Estonian: Subkutaanselt annuses 0,25-3 mg/kg manustatuna näitas maropitant lineaarset farmakokineetikat.
English: • For the prevention of vomiting induced by motion sickness.
Estonian: • Kinetoosist e. merehaigusest tingitud oksendamise ärahoidmiseks.
English: * Correct dose for dogs of less than 3 kg cannot be accurately achieved.
Estonian: * sobivat annust alla 3kg kaaluvatele koertel pole võimalik täpselt doseerida Merehaiguse ärahoidmiseks, (ainult 16-nädalastele või vanematele koertele)
English: Maropitant displays linear kinetics when administered subcutaneously within the 0.5-2 mg/kg dose range.
Estonian: Subkutaanselt annuses 0,5−2 mg/kg manustatuna näitas maropitant lineaarset farmakokineetikat.
English: Prevention of nausea induced by chemotherapy Treatment and prevention of vomiting (except motion sickness) Dog body weight (kg)
Estonian: Kemoteraapiast tingitud iivelduse ärahoidmiseks Oksendamise raviks ja ärahoidmiseks (v.a. merehaigus)
English: Pale orange tablet
Estonian: Kahvatuoranž tablett.
English: Maropitant is metabolised in the liver and therefore should be used with caution in dogs with liver disease.
Estonian: Maropitandil on afiinsus kaltsiumi ja kaaliumi ioonkanalite suhtes, seetõttu tuleks südamehaigusega või südamehaiguste eelsoodumusega loomadel Cereniat kasutada ettevaatlikult.
English: Further information on ProZinc can be found on the Agency's website: ema.europe.eu/medicines/veterinary/EPAR/prozinc
Estonian: Lisateave ProZinci kohta on ameti veebilehel: ema.europe.eu/medicines/veterinary/EPAR/prozinc.
English: ProZinc (human insulin)
Estonian: ProZinc (iniminsuliin)
English: For dogs, if there is insufficient response to treatment after 4 - 6 weeks, the dose and/or frequency can be changed.
Estonian: Kui koera ravivastus on 4-6 nädala järel ebapiisav, võib annust ja/või sagedust muuta.
English: There is a low chance of an allergic reaction in sensitised people.
Estonian: Sensibiliseeritud inimestel esineb ka allergilise reaktsiooni väike risk.
English: The European Medicines Agency decided ProZinc's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et ProZinci kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise saab Euroopa Liidus heaks kiita.
English: These hypoglycaemic events are generally mild in nature.
Estonian: Need hüpoglükeemianähud on üldjuhul kerged.
English: ProZinc (human insulin) EMA/300817/2013
Estonian: ProZinc (iniminsuliin) EMA/300817/2013
English: It is given as an injection under the skin twice daily for cats and once daily for dogs either at the same time or immediately after a meal.
Estonian: Ravimit manustatakse subkutaanse (nahaaluse) süstena kassidele kaks korda ööpäevas ja koertele üks kord ööpäevas kas söögi ajal või vahetult pärast sööki.
English: ProZinc received a marketing authorisation valid throughout the EU on 12 July 2013.
Estonian: ProZinci müügiluba, mis kehtib kogu Euroopa Liidus, anti 12. juulil 2013.
English: After 12 weeks, 113 out of 134 ProZinc treated dogs (84%) were successfully treated, compared to 91 out of the 111 control dogs (82%).
Estonian: 12 nädala järel loeti ravi õnnestunuks 113 koeral 134 ProZinciga ravitud koerast (84%); kontrollrühmas oli see näitaja 91 koera 111st (82%).
English: What is ProZinc and what is it used for?
Estonian: Mis on ProZinc ja milleks seda kasutatakse?
English: Because of its prolonged action, it must also not be used for the short-term management of diabetic ketoacidosis (a serious complication of diabetes with high levels of ketones in the blood).
Estonian: Ravimit ei tohi selle pikaajalise toime tõttu kasutada ka diabeetilise ketoatsidoosi (diabeedi raske tüsistus, millega kaasneb vere suur ketoonisisaldus) lühiajaliseks ohjamiseks.
English: ProZinc must not be used in cats or dogs which are hypersensitive (allergic) to insulin or any of the other ingredients.
Estonian: ProZinci ei tohi kasutada kassidel ja koertel, kes on insuliini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: It contains the active substance human insulin.
Estonian: Ravim sisaldab toimeainena iniminsuliini.
English: A glucose containing solution or gel and/or food is required to be given to the animal immediately.
Estonian: Loomale tuleb siis kohe anda glükoosi sisaldavat lahust või geeli ja/või toitu.
English: Other information about ProZinc
Estonian: Muu teave ProZinci kohta
English: Diabetes is a disease in which the pancreas does not make enough insulin to control the level of blood glucose (sugar) and/or when the body is unable to use insulin effectively.
Estonian: Diabeet on haigus, mille korral kõhunäärmes ei teki vere glükoosisisalduse (veresuhkru) reguleerimiseks piisavalt insuliini ja/või organism ei suuda insuliini efektiivselt kasutada.
English: These are absorbed more slowly after injection and take longer to reach their target in the body than naturally produced insulin.
Estonian: Nii imendub insuliin pärast süstet kauem ja jõuab organismis aeglasemalt sihtmärgini kui organismis looduslikult tekkiv insuliin.
English: If the product is accidentally self-injected, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
Estonian: Ravimi juhuslikul enesesüstimisel tuleb viivitamatult pöörduda arsti poole ja näidata arstile pakendi infolehte või etiketti.
English: ProZinc is a veterinary medicine used to treat cats and dogs with diabetes.
Estonian: ProZinc on veterinaarravim, millega ravitakse diabeediga kasse ja koeri.
English: The most common side effect during treatment with ProZinc (which may affect more than 1 in 10 animals) is hypoglycaemia (low blood glucose levels) which may result in signs such as hunger, anxiety, unsteady movement, muscle twitching, stumbling or sinking in the rear legs and disorientation.
Estonian: ProZinci-ravi kõige sagedam kõrvalnäht (võib esineda enam kui 1 loomal 10st) on hüpoglükeemia (vere väike glükoosisisaldus), mis võib põhjustada selliseid sümptomeid nagu nälg, ärevus, liigutuste ebakindlus, lihasetõmblused, komistamine või tagajalgade vajumine ja orienteerumatus.
English: For a full list of the side effects and restrictions with ProZinc, see the package leaflet.
Estonian: ProZinci kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The correct dose is determined individually for each animal depending on weight and needs to be adjusted depending on the response to treatment.
Estonian: Ravimi annus määratakse looma kehakaalu põhjal ja seda kohandatakse ravivastuse järgi.
English: In an EU field study involving diabetic dogs, ProZinc was as effective as an authorised veterinary insulin, with improvement of at least one blood sugar measurement and at least one of three clinical signs: bodyweight, polyuria and polydipsia.
Estonian: Diabeediga koerte ELi väliuuringus osutus heakskiidetud veterinaarinsuliinina kasutatav ProZinc efektiivseks: paranes vähemalt üks vere glükoosisisalduse näitaja ja vähemalt üks kolmest kliinilisest sümptomist: kehamass, polüuuria ja polüdipsia.
English: For more information about using ProZinc, see the package leaflet or contact your veterinarian or pharmacist.
Estonian: Kui vajate ProZinciga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte või pöörduge oma veterinaararsti või apteekri poole.
English: In a field study involving 139 diabetic cats of various ages and breeds, after 6 weeks of treatment with ProZinc average blood sugar levels decreased and clinical signs improved, for example average body weight increased; 116 out of 139 cats (84%) were considered to be treated successfully.
Estonian: Väliuuringus, mis hõlmas 139 eri vanuses ja tõugudest kassi, kellel oli diabeet, vähenes pärast 6nädalast ravi ProZinciga vere keskmine glükoosisisaldus ja paranesid kliinilised sümptomid, näiteks suurenes keskmine kehamass; ravi loeti õnnestunuks 116 kassil 139st (84%).
English: An overview of ProZinc and why it is authorised in the EU
Estonian: ProZinci ülevaade ja Euroopa Liidus heakskiitmise põhjused
English: What are the risks associated with ProZinc?
Estonian: Mis riskid ProZinciga kaasnevad?
English: Accidental self-injection can result in clinical signs of low blood glucose levels which can be treated by taking sugar by mouth.
Estonian: Juhuslik enesesüstimine võib põhjustada vere väikese glükoosisisalduse kliinilisi sümptome, mida saab ravida, süües suhkrut.
English: ProZinc can only be obtained with a prescription and is available as a suspension for injection (40 IU/ml).
Estonian: ProZinc on retseptiravim ja seda turustatakse süstelahusena (40 IU/ml).
English: How does ProZinc work?
Estonian: Kuidas ProZinc toimib?